Assessment of lymphatic impairment and interstitial protein accumulation in patients with breast cancer treatment-related lymphedema using CEST MRI.
Assessment of lymphatic impairment and interstitial protein accumulation in patients with breast cancer treatment-related lymphedema using CEST MRI.
复制标题
DOI：
10.1002/mrm.25649
复制
发表时间：
2016-01
影响因子：
3.3
通讯作者：
Smith SA
中科院分区：
文献类型：
--
作者：
Donahue MJ;Donahue PC;Rane S;Thompson CR;Strother MK;Scott AO;Smith SA
Lymphatic impairment is known to reduce quality of life in some of the most crippling diseases of the 21st century, including obesity, lymphedema, and cancer. However, the lymphatics are not nearly as well-understood as other bodily systems, largely owing to a lack of sensitive imaging technologies that can be applied using standard clinical equipment. Here, proton exchange-weighted MRI is translated to the lymphatics in patients with breast cancer treatment-related lymphedema (BCRL). Healthy volunteers (N=8) and BCRL patients (N=7) were scanned at 3T using customized structural MRI and amide proton transfer (APT) chemical exchange saturation transfer (CEST) MRI in sequence with the hypothesis that APT effects would be elevated in lymphedematous tissue. APT contrast, lymphedema stage, symptomatology, and histology information were evaluated. No significant difference between proton-weighted APT contrast in the right and left arms of healthy controls was observed. An increase in APT contrast in the affected arms of patients was found (P=0.025; Cohen’s d=2.4), and variability among patients was consistent with documented damage to lymphatics as quantified by lymphedema stage. APT CEST MRI may have relevance for evaluating lymphatic impairment in patients with BCRL, and may extend to other pathologies where lymphatic compromise is evident.
